4D Pharma PLC Warrant
LBPSW
LBPSW was delisted on the 29th of June, 2022.
6 hedge funds and large institutions have $202K invested in 4D Pharma PLC Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
93% less capital invested
Capital invested by funds: $2.81M → $202K (-$2.61M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$11.3K |
| 2 |
Walleye Capital
New York
|
+$6.63K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$750 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$3.75K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$2.07K |
LBPSW Hedge Fund Activity: Q1 2022 in Review
6 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC Warrant (LBPSW) for Q1 2022, worth a combined $202K — down 93% from $2.81M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new LBPSW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was AQR Arbitrage, adding an estimated $11.3K. The largest seller was HRT Financial, cutting an estimated $3.75K.
- 6 institutional investors held 4D Pharma PLC Warrant (LBPSW) as of Q1 2022, up from 5 in Q4 2021.
- Funds reported $202K of 4D Pharma PLC Warrant stock for Q1 2022, down 93% quarter-over-quarter.
- 1 fund opened new 4D Pharma PLC Warrant positions in Q1 2022 and 0 closed out, a net change of +1 holder.
- The largest 4D Pharma PLC Warrant buyer in Q1 2022 was AQR Arbitrage, an estimated $11.3K added.
- The largest 4D Pharma PLC Warrant seller in Q1 2022 was HRT Financial, an estimated $3.75K sold.
Based on aggregated 13F filings for Q1 2022.